AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32029429 — intervention group
Group type: COMPARATOR
Intervention: Endometrial injection of 99m Tc into the fundal endometrium using a transcervical catheter
Number of subjects: 81
Study 33506983 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus (LL) position
Number of subjects: 212
Study 33506983 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 212
Study 35253570 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum neurofilament light (NFL) sampled 48/72-hours post-arrest
Number of subjects: 457
Study 35253570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral Performance Category (CPC)
Number of subjects: 457
Study 35253570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 457
Study 32804388 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-elastic bougie (GEB)
Number of subjects: 50
Study 32804388 — intervention group
Group type: COMPARATOR
Intervention: Semirigid stylet
Number of subjects: 50
Study 35256388 — intervention group
Group type: EXPERIMENTAL
Intervention: Small Change Approach (SCA)
Number of subjects: 320
Study 35256388 — intervention group
Group type: COMPARATOR
Intervention: Monitoring Alone (MA)
Number of subjects: 320
Study 33872709 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 48
Study 33872709 — intervention group
Group type: COMPARATOR
Intervention: Control (stretching exercise)
Number of subjects: 48
Study 32739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred revascularization based on fractional flow reserve in ACS patients
Number of subjects: 8579
Study 32739305 — intervention group
Group type: COMPARATOR
Intervention: Deferred revascularization based on fractional flow reserve in SAP patients
Number of subjects: 8579
Study 32739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplanned revascularization in ACS patients
Number of subjects: 8579
Study 32739305 — intervention group
Group type: COMPARATOR
Intervention: Unplanned revascularization in SAP patients
Number of subjects: 8579
Study 32739305 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (both ACS and SAP)
Number of subjects: 8579
Study 35973188 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshwater fish-based diet (F group)
Number of subjects: 34
Study 35973188 — intervention group
Group type: COMPARATOR
Intervention: Freshwater fish-based and red meat-based diets alternately (F/M group)
Number of subjects: 34
Study 34370587 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 76
Study 34370587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole
Number of subjects: 76
Study 36149164 — intervention group
Group type: COMPARATOR
Intervention: Conventional field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Number of subjects: 50
Study 36149164 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field EBRT 50 Gy with concurrent weekly chemotherapy followed by ICBT
Number of subjects: 50
Study 32839849 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest autograft
Number of subjects: 46
Study 32839849 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest allograft
Number of subjects: 46
Study 35610014 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuling decoction
Number of subjects: 96
Study 35610014 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 96
Study 33482853 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (BBR)
Number of subjects: 118
Study 33482853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 33300853 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic rehydration (oral fluid consumption)
Number of subjects: 10
Study 33300853 — intervention group
Group type: COMPARATOR
Intervention: Local rehydration (nebulized isotonic saline)
Number of subjects: 10
Study 33300853 — intervention group
Group type: COMPARATOR
Intervention: Dehydration (exercise in heat or fluid restriction)
Number of subjects: 10
Study 32325164 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose water (D5W) and corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Number of subjects: 36
Study 32325164 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (triamcinolone acetonide, 10mg/mL) injection
Number of subjects: 36
Study 32007991 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) method, implemented for 72 treatment sessions, 3 times a week for 24 weeks
Number of subjects: 90
Study 32007991 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR) method
Number of subjects: 90
Study 34243836 — intervention group
Group type: EXPERIMENTAL
Intervention: TYRX Absorbable Antibacterial Envelope adjunctive to standard of care
Number of subjects: 3
Study 34243836 — intervention group
Group type: COMPARATOR
Intervention: Standard of care infection prevention alone
Number of subjects: 3
Study 33050401 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered dietary intervention
Number of subjects: 155
Study 33050401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study 35815323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical injection of combination liposomal bupivacaine and bupivacaine
Number of subjects: 60
Study 35815323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 33539955 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive tablets containing cilnidipine
Number of subjects: 0
Study 33539955 — intervention group
Group type: COMPARATOR
Intervention: Reference tablets
Number of subjects: 0
Study 32145522 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic
Number of subjects: 41
Study 32145522 — intervention group
Group type: COMPARATOR
Intervention: Sensorimotor
Number of subjects: 41
Study 35316101 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial middle turbinate resection
Number of subjects: 49
Study 33341816 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorful Semantics (CS) protocol in augmentative communication (AC) intervention
Number of subjects: 40
Study 33341816 — intervention group
Group type: COMPARATOR
Intervention: Control group AC intervention without CS protocol
Number of subjects: 40
Study 32463519 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block of nerves T18, L1, and L2
Number of subjects: 12
Study 32463519 — intervention group
Group type: COMPARATOR
Intervention: Local portal blocks of the three laparoscopic portals
Number of subjects: 12
Study 34483276 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg height-based dosing) administered 4 times per year for 1 year
Number of subjects: 1255
Study 34483276 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1255
Study 34236905 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 22
Study 34236905 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 22
Study 33728657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 108
Study 33728657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive Pill (COCP)
Number of subjects: 108
Study 33728657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33989386 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-read sequencing technology combined with RNA-seq for transcriptomic analysis
Number of subjects: 0
Study 33989386 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-read sequencing technology combined with RNA-seq
Number of subjects: 0
Study 32699126 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve-week Slimming World (SW) commercial group weight management programme, commencing anytime from 8 to 16 weeks postnatally.
Number of subjects: 98
Study 35544137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive trial design
Number of subjects: 1151
Study 35544137 — intervention group
Group type: COMPARATOR
Intervention: Frequentist adaptive trial design
Number of subjects: 1151
Study 36265101 — intervention group
Group type: COMPARATOR
Intervention: Triple metronomic chemotherapy (TMC): oral methotrexate 9 mg/m2 once a week, celecoxib 200 mg twice daily, erlotinib 150 mg once daily
Number of subjects: 151
Study 36265101 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC with intravenous nivolumab (TMC-I): TMC plus nivolumab 20 mg flat dose once every 3 weeks
Number of subjects: 151
Study 36265101 — intervention group
Group type: COMPARATOR
Intervention: TMC
Number of subjects: 151
Study 36265101 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC-I
Number of subjects: 151
Study 34440949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst Stimulation (cTBS) - 2400 pulses/day for 5 days
Number of subjects: 15
Study 34440949 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 34928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (ILE) - 100 ml of 20% ILE bolus followed by 100 ml of 20% ILE infusion over 6 hours
Number of subjects: 45
Study 34928182 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 45
Study 34928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion (ILE)
Number of subjects: 45
Study 34102144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) combined with standard care (4×4 minutes of treadmill HIIT at 85%-95% of peak heart rate)
Number of subjects: 70
Study 34102144 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) combined with standard care
Number of subjects: 70
Study 34102144 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 70
Study 34275209 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 73
Study 34275209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 32275359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needling treatment (at Lianquan (CV 23), Fengchi (GB 20), Wangu (GB 12), Shuigou (GV 26), Neiguan (PC 6), and Zusanli (ST 36) without needle retaining every other day)
Number of subjects: 76
Study 32275359 — intervention group
Group type: COMPARATOR
Intervention: Swallowing function rehabilitation training (control group)
Number of subjects: 76
Study 34732586 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive-pressure extubation technique (application of pressure support mode at 15/10 cm H2O during cuff deflation and extubation)
Number of subjects: 725
Study 34732586 — intervention group
Group type: COMPARATOR
Intervention: Traditional extubation technique (removing the endotracheal tube by applying continuous endotracheal suctioning during the entire procedure)
Number of subjects: 725
Study 34154510 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 34154510 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 0
Study 34154510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32734378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS combined with visual feedback
Number of subjects: 90
Study 32734378 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback alone
Number of subjects: 90
Study 32734378 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 90
Study 32734378 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 90
Study 34349248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactococcus lactis subsp. cremoris YRC3780
Number of subjects: 27
Study 34349248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 32016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with simethicone
Number of subjects: 128
Study 32016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with simethicone plus NAC 600 mg
Number of subjects: 128
Study 32016519 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with simethicone, NAC, sodium bicarbonate and peppermint
Number of subjects: 128
Study 32016519 — intervention group
Group type: COMPARATOR
Intervention: Water (Control Group A)
Number of subjects: 128
Study 34040762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin tablets
Number of subjects: 204
Study 34040762 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin tablets
Number of subjects: 204
Study 34040762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 35505174 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg intravenous rhPro‐UK (n = 40)
Number of subjects: 119
Study 35505174 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg intravenous rhPro‐UK (n = 39)
Number of subjects: 119
Study 35505174 — intervention group
Group type: COMPARATOR
Intervention: 0.9 mg/kg recombinant tissue plasminogen activator (r‐tPA; n = 40)
Number of subjects: 119
Study 35505174 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 119
Study 34010810 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for empowerment (experimental group)
Number of subjects: 24
Study 34010810 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 24
Study 36334720 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1 mg intranasal spray (neffy)
Number of subjects: 175
Study 36334720 — intervention group
Group type: COMPARATOR
Intervention: Manual intramuscular epinephrine 0.3 mg injection
Number of subjects: 175
Study 36334720 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 0.3 mg autoinjectors (Symjepi)
Number of subjects: 175
Study 36334720 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 0.3 mg autoinjectors (EpiPen)
Number of subjects: 175
Study 33998369 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated malingering group (n = 50)
Number of subjects: 100
Study 33998369 — intervention group
Group type: COMPARATOR
Intervention: Best-effort/control group (n = 50)
Number of subjects: 100
Study 32147750 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-07A 10 mg
Number of subjects: 36
Study 32147750 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-07A 20 mg
Number of subjects: 36
Study 32147750 — intervention group
Group type: EXPERIMENTAL
Intervention: SPT-07A 40 mg
Number of subjects: 36
Study 32147750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33307959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine antagonist
Number of subjects: 17
Study 33307959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist
Number of subjects: 17
Study 33307959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 32616246 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (1.5%)
Number of subjects: 360
Study 32616246 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil (1.5%)
Number of subjects: 360
Study 32616246 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (1.5%)
Number of subjects: 360
Study 32616246 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (1.5%)
Number of subjects: 360
Study 34146915 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFAs)
Number of subjects: 0
Study 34146915 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acids (SFAs)
Number of subjects: 0
Study 34146915 — intervention group
Group type: COMPARATOR
Intervention: Polyunsaturated fatty acids (PUFAs)
Number of subjects: 0
Study 33103929 — intervention group
Group type: EXPERIMENTAL
Intervention: Influencers with broad smiles
Number of subjects: 0
Study 33103929 — intervention group
Group type: COMPARATOR
Intervention: Influencers with closed smiles
Number of subjects: 0
Study 34332616 — intervention group
Group type: EXPERIMENTAL
Intervention: CBM‐IClin intervention (four sessions at home)
Number of subjects: 0
Study 34332616 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 35239511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut decontamination (GD) with oral vancomycin-polymyxin B from day -5 through neutrophil engraftment
Number of subjects: 20
Study 35239511 — intervention group
Group type: COMPARATOR
Intervention: No gut decontamination (no-GD)
Number of subjects: 20
Study 35239511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut decontamination (GD)
Number of subjects: 20
Study 32978183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving care accompanied by reinstruction and remotivation by dental assistants using the 'Oral Health Toolbox'.
Number of subjects: 618
Study 32978183 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving care as usual.
Number of subjects: 618
Study 32978183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group.
Number of subjects: 618
Study 32978183 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 618
Study 33558263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin plus epinephrine (EI)
Number of subjects: 548
Study 33558263 — intervention group
Group type: COMPARATOR
Intervention: Rectal indomethacin plus sterile water (WI)
Number of subjects: 548
Study 33558263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct guidewire insertion
Number of subjects: 548
Study 32407060 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery
Number of subjects: 0
Study 32407060 — intervention group
Group type: COMPARATOR
Intervention: Traditional rotary burs
Number of subjects: 0
Study 35777882 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Computerised Cognitive Training (CCT)
Number of subjects: 200
Study 35777882 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based diet
Number of subjects: 200
Study 35777882 — intervention group
Group type: COMPARATOR
Intervention: Basic Computerised Cognitive Training (CCT)
Number of subjects: 200
Study 35777882 — intervention group
Group type: COMPARATOR
Intervention: Healthy diet following the current guidelines of the German Nutrition Society
Number of subjects: 200
Study 33934456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon (0.6 mg)
Number of subjects: 42
Study 33934456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 33934456 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted glucagon (GlucaGen)
Number of subjects: 42
Study 32320844 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care program
Number of subjects: 345
Study 32320844 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 345
Study 35946884 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy + resistance training (TG)
Number of subjects: 30
Study 35946884 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy (CG)
Number of subjects: 30
Study 34547165 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping with manual therapy (KTMT)
Number of subjects: 0
Study 34547165 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MT)
Number of subjects: 0
Study 32030508 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 30
Study 32030508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33566629 — intervention group
Group type: EXPERIMENTAL
Intervention: NACD+PRP
Number of subjects: 80
Study 33566629 — intervention group
Group type: COMPARATOR
Intervention: NACD+corticosteroids
Number of subjects: 80
Study 32233001 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (two-day intensive workshop combining reading materials)
Number of subjects: 37
Study 32233001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 34166810 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐confident model
Number of subjects: 60
Study 34166810 — intervention group
Group type: EXPERIMENTAL
Intervention: Unself‐confident model
Number of subjects: 60
Study 34166810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 36176051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 30–720 mg vutiglabridin
Number of subjects: 0
Study 36176051 — intervention group
Group type: EXPERIMENTAL
Intervention: 240–480 mg vutiglabridin once daily for 14 days
Number of subjects: 0
Study 36176051 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg single dose of vutiglabridin with a high-fat meal
Number of subjects: 0
Study 36176051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32678452 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled vaporized cannabis (4.4% Δ‐9‐tetrahydrocannabinol to 4.9% cannabidiol) 3 times daily for 5 days
Number of subjects: 27
Study 32678452 — intervention group
Group type: COMPARATOR
Intervention: Inhaled vaporized placebo cannabis 3 times daily for 5 days
Number of subjects: 27
Study 32678452 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled vaporized cannabis
Number of subjects: 27
Study 32678452 — intervention group
Group type: COMPARATOR
Intervention: Inhaled vaporized placebo cannabis
Number of subjects: 27
Study 34473026 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI
Number of subjects: 201
Study 34473026 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CRP
Number of subjects: 201
Study 34473026 — intervention group
Group type: EXPERIMENTAL
Intervention: Long duration of cardiopulmonary bypass
Number of subjects: 201
Study 34473026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative anemia
Number of subjects: 201
Study 34473026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CRP concentration
Number of subjects: 201
Study 33225642 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ERM peeling alone (Group A)
Number of subjects: 44
Study 33225642 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ERM and ILM peeling (Group B)
Number of subjects: 44
Study 33225642 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 44
Study 35678800 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg/day orally for 12 weeks)
Number of subjects: 74